We described the development and full validation of a rapid, high throughput sensible and
accurate LC method using tandem mass spectrometry detection for determining apixaban …

A simple, robust, and stability-indicating reversed-phase high-performance liquid
chromatographic (HPLC) method for the analysis of apixaban and its related substances has …

Background: apixaban (BMS-562247)(Eliquis®) is a novel, orally active, selective, direct,
reversible inhibitor of the coagulation factor Xa (FXa). A sensitive and reliable method was …

Objective This was a randomized, placebo-controlled, double-blind, sequential, ascending-
dose study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of …

The risk of venous thromboembolism increases in patients post-surgically, such as affer hip
or knee replacement, fracture surgery, or atrial fibrillation.[1, 2] Generally, vitamin K …

Abstract Background and Objectives The effects of age and sex on apixaban
pharmacokinetics and pharmacodynamics were studied. Methods This was an open-label …

Background: Apixaban is an oral, potent, highly selective, reversible and direct inhibitor of
activated coagulation factor X, that is the end point of the intrinsic and extrinsic coagulation …

Apixaban (Eliquis™) was developed by Bristol-Myers Squibb (BMS) and Pfizer to use as an
antithrombotic/anticoagulant agent and has been recently approved for the prevention of …

While laboratory monitoring is not required in patients treated with apixaban, a direct factor-
Xa inhibitor, assessment of its concentration is useful in some critical situations. However …

Apixaban is an oral, direct factor Xa inhibitor that inhibits both free and clot-bound factor Xa,
and has been approved for clinical use in several thromboembolic disorders, including …